BioAtla, Inc. Cash Flow Statement
BCAB|2 years of annual SEC 10-K data (FY2021-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$90M
FY2022
Free Cash Flow
N/A
FY2022
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2022
BioAtla, Inc. used $90M in operating cash flow in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.29 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -59.1% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 |
|---|---|---|
| Net Income | -$106.5M | -$95.4M |
| Depreciation & Amortization | $1.2M | $1.3M |
| Operating Cash Flow | -$90.4M | -$62.2M |